Repligen
Repligen Corporation, a leading player in the bioprocessing industry, is headquartered in the United States. Founded in 1981, the company has established itself as a key provider of innovative solutions for the development and manufacture of biologics. With a strong presence in major operational regions including Europe and Asia, Repligen focuses on areas such as protein purification, cell culture, and bioprocessing technologies. The company’s core products, including its unique chromatography resins and single-use systems, are designed to enhance efficiency and productivity in biomanufacturing. Repligen's commitment to quality and innovation has positioned it as a trusted partner for biopharmaceutical companies worldwide. Notable achievements include significant growth through strategic acquisitions, solidifying its market position as a frontrunner in bioprocessing solutions.
DitchCarbon Score
How does Repligen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Repligen's score of 38 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Repligen's reported carbon emissions
In 2023, Repligen Corporation reported total carbon emissions of approximately 16,000,000 kg CO2e, comprising 2,236,000 kg CO2e from Scope 1, 959,000 kg CO2e from Scope 2, and 14,940,000 kg CO2e from Scope 3 emissions. This marked a significant increase in emissions compared to previous years, with total emissions in 2022 being about 16,377,000 kg CO2e. Repligen has committed to achieving net-zero emissions by 2050, as part of its long-term climate strategy. The company has set targets through the Science Based Targets initiative (SBTi), indicating a commitment to reducing emissions across all scopes. This commitment aligns with industry standards for climate action, reflecting Repligen's dedication to sustainability within the pharmaceuticals and biotechnology sector. The company has shown a progressive increase in emissions over the years, with Scope 1 and 2 emissions in 2022 being approximately 4,269,000 kg CO2e, up from about 3,250,000 kg CO2e in 2020. Despite the rising emissions, Repligen's long-term goals demonstrate a proactive approach to mitigating climate impact and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 517,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,219,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Repligen is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
